Founded in 1995 Inter-Med, Inc. has been conducting business as Vista Dental Products. Vista designs, manufactures and sells a broad range of dental products, including proprietary small equipment, engineered therapeutic solutions and pre-filled medicated syringes.

Over the years Inter-Med / Vista Dental has created a market reputation as a creative product developer. With 19 patents issued and 15+ more in applications on file, Inter-Med has demonstrated a stream of consciousness related to product development. Over the last 7+ years the Company has been actively developing products related to the early detection of oral cancer. In 2009 Inter-Med began pilot studies to investigate the use of optical molecular imaging as a viable method of detecting, with a high degree of specificity and sensitivity, early stage oral cancer and precancerous lesions. Inter-Med’s technology incorporates UV auto fluorescent technology along with fluorescent stains and molecular probes that highlight diseased lesions in the oral cavity with incredible sensitivity and specificity. These simple to use, non-staining fluorescent markers identify high nuclear content areas, while the molecular probe targets abnormal glycosylation which is a property universal to carcinogenesis.


Inter-Med has formed Visual Solutions as a single member limited liability company owned by the Company (Inter-Med). Through Visual Solutions, the Company intends to commercialize it’s oral cancer product with a strategy different from the Company’s Vista Dental strategy. This strategy will allow the following:

  • The Biotech nature of the device will require a more clinically oriented approach to market penetration.
  • The size of the market opportunity will require a focused infrastructure.
  • The Company’s current dealer network relationships and know-how can be developed.
  • The investment to support sales through dealers is similar to the investment to support direct sales.
  • The broad nature of Vista products threatens focus.
  • Facilitates a bifurcated exit strategy.

Visual Solutions will market its initial oral cancer product as ESPýOC™ while developing other mucosal applications for its patent pending technologies.


Despite refinement of surgical techniques and screening technologies, out of the 450,000 newly diagnosed cases of oral cancer each year, about half of these patients will die in the next five years. Early detection and treatment of cancers can markedly decrease mortality rates and increase survival rates. However, being unaided visually, clinicians face considerable challenges in identifying and differentiating lesion from normal tissues. Current screening methods require the practitioner to rely solely on visual and tactile oral inspections that can only be relied on to detect the most obvious lesions. Even for the most experienced Oral Surgeon oral abnormalities are often very difficult to observe and diagnose.

Scientists from the World Health Organization are predicting over the next 20 years greater than a 50% increase in the incidence of oral cancer [23]. Currently there is not a comprehensive program to adequately screen for the disease, despite several technologies being commercially available. In order to reduce the morbidity and mortality rate associated with oral cancer a non-invasive in-vivo screening method with molecular specificity is needed.

Visual Solutions’ patent pending device incorporates UV auto fluorescence technology along with fluorescent stains / molecular probes to highlight diseased lesions in the oral cavity with incredible sensitivity and specificity. The fluorescent stains identify high nuclear content areas while the molecular probe targets abnormal glycosylation which is a property universal to carcinogenesis. By targeting DNA/RNA rich areas and cell surface tumor related glycan signatures the device provides a mechanism for early identification and surveillance of oral cancerous and precancerous lesions.


Our team has tested not only ESPýOC™ but leading competitive products. The results are strong, reliable, and impressive. If you have any questions about performance, clinical trial tests, or would like further documentation please contact us.

To read about our studies, click this link for more information about Molecular Imaging of Oral Premalignant and Malignant Lesions Using Fluorescently Labeled Lectins Baeten 2014.